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Abstract
Alpinia pricei Hayata is a Formosan plant which has been popularly used as nutraceutical or folk medicine for
inflammation and various disorders. An active compound of the plant rhizomes, desmethoxyyangonin (DMY), was
identified in this study for its novel effect against endotoxin lipopolysaccharide (LPS)-stimulated inflammation in
murine macrophages and LPS/D-galactosamine (LPS/D-GalN)-induced fulminant hepatitis in mice. DMY was
observed to significantly inhibit proliferation and activation of T cells ex vivo and the activity of several pro-
inflammatory mediators in vitro. DMY also protected LPS/D-GalN−induced acute hepatic damages in mice through
inhibiting aminotransferases activities and infiltrations of inflammatory macrophages, neutrophils and pathogenic T
cells into the liver tissues. In addition, pretreatment with DMY significantly improved the survival rate of LPS/D-GalN
−treated mice to 90% (9/10), compared to LPS/D-GalN−treated group (40%, 4/10). UPLC/MS platform-based
comparative metabolomics approach was used to explore the serum metabolic profile in fulminant hepatic failure
(FHF) mice with or without the DMY pretreatment. The results showed that LPS/D-GalN−induced hepatic damage is
likely through perturbing amino acid metabolism, which leads to decreased pyruvate formation via catalysis of
aminotransferases, and DMY treatment can prevent to a certain degree of these alterations in metabolic network in
mouse caused by LPS/D-GalN. Mechanistic investigation demonstrated that DMY protects LPS or LPS/D-GalN
−induced damages in cell or liver tissues mainly through de-regulating IKK/NFκB and Jak2/STAT3 signaling
pathways. This report provides evidence-based knowledge to support the rationale for the use of A. pricei root extract
in anti-inflammation and also its new function as hepatoprotetive agent against fulminant hepatitis.
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Introduction
Inflammation is a syndrome responsive to pathogen infection
or injury. Stimuli−induced production of pro-inflammatory
mediators in macrophages, such as TNF-α and NO can cause
acute inflammatory responses and may result in inflammatory
diseases. LPS from the outer membrane of Gram-negative
bacteria promotes secretion of the pro-inflammatory mediators
by interacting with the CD14/Toll-like receptor 4/MD2 receptor
complex in many cell types such as macrophages and
endothelial cells [1]. LPS can induce mRNA or protein levels of
iNOS, which catalyzes oxidative deamination of L-arginine to
produce NO. In the liver, LPS promotes NO production to
induce inflammation and liver toxicity by activating iNOS in
Kupffer cells, endothelial cells and hepatocytes [2]. As well,
some plant natural compounds such as curcumin and tea
polyphenols possess hepatoprotective functions by inhibiting
iNOS in LPS–induced liver damage [3].
NF-κB plays an important role in regulating LPS−stimulated
inflammatory mediators. Activation of NF-κB in response to
inflammatory stimuli involves degradation of IκB via cascade
activities by phosphorylation of the IKK complex and results in
nuclear translocation of NF-κB to bind to the cis-element in the
promoter regions of various genes such as iNOS and COX-2,
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thereby inducing their overexpression [4]. The MAPK family
members, ERK1/2 and JNK, are signaling molecules that also
react to extracellular stimuli and regulate pro-inflammatory
cytokine production [5]. Furthermore, STAT3 is involved in
inflammatory responses: tyrosine phosphorylation at residue
705 on STAT3 promotes the production of pro-inflammatory
cytokines such as IL-6 in LPS−stimulated macrophages [6].
Fulminant hepatic failure (FHF) is associated with severe
liver disorders that result in rapid distortion of hepatic function.
It is a life-threatening disease, with orthotopic liver
transplantation as the only curative treatment at present [7].
Therefore, discovery of effective therapies against FHF is
urgently needed. Alpinia pricei Hayata (Zingiberaceae) is one
of 8 endemic species of Alpinia genus in Taiwan. It is
commonly found in wild fields and low-attitude mountain areas
and frequently used as nutraceuticals or folk medicine for
curing flatulence, inflammation, and digestive disturbance.
Recent in vitro and in vivo studies have shown that ethanol
extracts of rhizomes of A. pricei have bioactivities, such as
anticancer [8,9] and improving metabolic syndrome [10]. Chang
et al. (2010) identified 3 major compounds,
desmethoxyyangonin (DMY), cardamonin, and flavokawain B,
from the ethanol extracts of A. pricei rhizome and suggested
that the extracts had both suppressive and preventive potency
against hypercholesterolemia by reducing serum total
cholesterol and low-density lipoprotein-cholesterol levels in test
animals [11].
In the present study, we showed that DMY inhibited LPS
−induced production of NO and iNOS expression in murine
RAW 264.7 macrophages. Moreover, DMY effectively
prevented LPS/D-GalN–induced acute hepatitis in ICR mice.
We used comparative metabolomics with UPLC/Q-TOF mass
spectrometry, along with multivariate PLS-DA, to characterize
the primary metabolic profile in LPS/D-GalN−challenged mice
with or without DMY treatment. This is the first study to
elucidate the hepatoprotective activity of DMY and the
underlying mechanistic insights.
Materials and Methods
Isolation and Structure Elucidation of DMY
The roots of A. pricei Hayata (Zingiberaceae) were collected
from Ping-Tung County located in south Taiwan in March 2007
and were identified by Professor Yen-Hsueh Tseng (National
Chung Hsing University). The voucher specimen was
deposited in the herbarium of National Museum of Natural
Science, Taichung, Taiwan (http://catalog.digitalarchives.tw/
item/00/61/e8/e2.html).The air-dried roots (2 kg) were extracted
with 10 L 70% ethanol (EtOH) in H2O at room temperature. The
total crude extract was evaporated to yield the EtOH extract
(APE) (166 g). The APE was separated by semi-preparative
HPLC. A Luna silica column (250 × 10 mm, Phenomenex Co.)
was used with 2 solvent systems, H2O (A) and 100%
acetonitrile (B). The gradient elution profile was as follows: 0-3
min, 80% A to B; 3-60 min, 80-0% A to B (linear gradient);
60-80 min 0% A to B. The flow rate was 2.5 ml/min and the
detector wavelength was set at 280 nm. DMY in the APE was
obtained at retention time 32.5 min. The structure of DMY was
elucidated by various spectroscopic analyses. UV spectra of
test compounds were recorded with use of a Jasco V-550
spectrometer and IR spectra were obtained with a Bio-Rad
FTS-40 spectrophotometer. Data from electron-impact MS and
high-resolution electron-impact MS were collected with use of a
Finnigan MAT-958 mass spectrometer and NMR spectra were
recorded with Bruker Avance 500 and 300 MHz FT-NMR
spectrometers, at 500 MHz (1H) and 75 MHz (13C). The
structure of DMY (Figure 1A) was elucidated and further
confirmed with previously published spectroscopic data [12].
Chemicals and Reagents
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), D-GalN, LPS, and 4,6-diamidino-2-phenylindole (DAPI)
were from Sigma Chemical Co. (St. Louis, MO, USA). DMEM,
fetal bovine serum (FBS), and the antibiotic mixture (penicillin-
streptomycin) were from Invitrogen (Carlsbad, CA, USA).
DMSO, silica gel and RP-18 F254 TLC plates were from Merck
(Darmstadt, Germany). RP-18 silica gel (75C18-OPN) was from
Nacalai Tesque (Kyoto, Japan). All other chemicals and
solvents were of reagent or HPLC grade.
Cell Lines and Culture Conditions
The murine macrophages RAW 264.7 and FL83B
hepatocyte cell line were obtained from the American Type
Culture Collection (Manassas, VA, USA). Both cell lines were
grown in DMEM (Gibco/BRL) supplemented with 10% heat-
inactivated FBS, 100 U/mL penicillin, and 100 µg/mL
streptomycin, at 37 °C in a humidified 5% CO2 incubator.
Animals
Male ICR mice were from the Laboratory Animal Center
(National Taiwan University, Taipei), given a standard
laboratory diet and distilled H2O ad libitum and kept on a 12 h
light/dark cycle at 22 ± 2 °C. All experimental protocols (No:
RMiIBASL2010044) were approved by the Institutional Animal
Care and Utilization Committee (IACUC), Academia Sinica,
Taiwan, R.O.C.
Measurement of NO Production and Cell Viability
Marcophages (2 × 105 cells/well in 96-well plate) were
treated with the indicated concentrations of DMY for 1 h, then
incubated for 24 h with or without 100 ng/µL LPS. Nitrite levels
in cell culture medium were determined by the Griess reaction
method. Cell viability was examined by MTT assay.
Reverse Transcriptase PCR (RT-PCR) and Western Blot
Analysis
RT-PCR analysis of iNOS expression and total cellular
protein extraction and preparation of cytosolic and nuclear
proteins from macrophages were as described [13]. Protein
concentration was determined by the Bradford method (Bio-
Rad). Protein samples were resolved by 5% to 20% gradient
SDS-PAGE and then underwent immunoblotting. Primary
antibodies against IκBα, ERK1/2, (JNK1/2, STAT1 and STAT3,
α-tubulin, Jak2, and IKK were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), iNOS, PARP, SOCS3, pTyr701-STAT1,
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Figure 1.  Desmethoxyyangonin (DMY) suppresses pro-inflammatory mediator activity in LPS−stimulated
macrophages.  (A) Chemical structure of DMY. (B) Inhibition of NO production. Bar graphs: % of NO inhibition; line graphs: relative
cell viability (%) by MTT assay. (C) Effect of DMY on iNOS mRNA expression. Cells were treated with the indicated concentrations
of DMY for 1 h and then LPS (100 ng/mL) for 6 h. Quantification of iNOS mRNA expression was normalized to GA3PDH by
densitometry. Relative ratios are to LPS treatment alone. (D) Effect of DMY on iNOS protein expression. Cells were treated with the
indicated concentrations of DMY for 1 h and then LPS (100 ng/mL) for 18 h. Total cellular proteins (30 µg) were resolved by SDS-
PAGE and immunoblotted with specific iNOS antibody. Level of iNOS protein was normalized to that of actin, and relative ratios are
to LPS treatment alone. (E) Inhibitory effect of DMY on TNF-α and IL-6 secretion. Macrophages (1 × 105 cells/well in 96-well plates)
were treated with the indicated concentrations of DMY for 6 h and then stimulated with LPS (100 ng/mL) for 12 h. Data are mean ±
SEM, n = 3. Means without a common letter differ, P < 0.05.
doi: 10.1371/journal.pone.0077626.g001
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pTyr705-STAT3, phospho-ERK1/2, -JNK1/2, -IκBα, -IKK, and -
Jak2 were from Cell Signaling Technology (Danvers, MA, USA)
and actin was from Chemicon International (Chemicon-
Millipore, Billerica, MA, USA). Appropriate horseradish
peroxidase-conjugated secondary antibodies were used.
Western blot analysis was performed as described [13]. Protein
bands reacting to specific antibody were visualized by use of
enhanced chemiluminescence (Amersham) with exposure to
chemiluminescence light film (BioMax; Kodak Co.). The
resulting images were quantified by densitometry and use of
Bio-Profil (Bio-1D 97.04, Vilber-Lourmat).
Enzymatic Activity Assay of iNOS
Effect of DMY on the enzymatic activity of iNOS enzyme was
determined by assessing conversion of substrate L-[14C]
arginine to product L-[14C] citrulline using a NOS activity assay
kit from Cayman Chemical (USA).
Measurement of TNF-α and IL-6 Production in
Macrophages
Macrophages (1 × 105 cells/well in 96-well plate) were
treated with DMY for 6 h and then LPS (100 ng/mL) for 18~24
h. The concentrations of TNF-α and IL-6 in culture medium
were determined by use of ELISA kits from R&D Systems
(Minneapolis, MN, USA).
[3H]Thymidine Incorporation Assay and Determination
of IL-2 Level Secreted by CD4+ Cells
Splenic CD4+ T cells were purified from male ICR mice (4
weeks old) using MACS columns (Miltenyi Biotech) and
stimulated with anti-CD3 (0.5 µg/mL) and anti-CD28 (0.5
µg/mL) mAbs in the presence of 0, 25, 50, or 100 µM of DMY,
or vehicle alone for 48 h. The IL-2 level secreted in cultural
media was determined by the use of an ELISA kit from R&D
Systems (Minneapolis, MN, USA). After an 8-h [3H]thymidine
pulse, the cells were harvested and counted in a PerkinElmer
scintillation counter.
Effect of DMY on Acute Fulminant Hepatitis in Mice
The in vivo protective effect of DMY on LPS/D-GalN-induced
fulminant hepatitis in ICR mice (4 weeks old) was investigated.
In total, 24 mice were randomly assigned to 4 groups (n = 6 per
group) for treatment: vehicle (0.5% DMSO); LPS/D-GalN; 1
mg/kg DMY; and 10 mg/kg DMY. The mice were given
intraperitoneally (i.p.) with low and high dose of DMY,
respectively for 3 consecutive days and 1 h before injection
with 500 ng LPS and 25 mg D-GalN in 250 µL saline. Blood
samples were collected by retro-orbital bleeding 8 h after
LPS/D-GalN injection, then mice were sacrificed, and serum
and liver tissues were collected.
Measurement of Serum AST and ALT Activities
Blood samples of test mice were centrifuged at 1400 g at 4
°C for 15 min, and AST and ALT activities in serum
supernatants were determined by use of commercial kits from
Randox Laboratories (UK).
Histology and Immunohistochemistry
Fresh liver tissues were fixed in 10% buffered formalin and
then embedded in paraffin. Paraffin-embedded liver samples
were sectioned (8 µm) and underwent hematoxylin and eosin
(H&E) staining. The formalin-fixed and paraffin-embedded liver
sections (4 µm thick) were heat immobilized and deparaffinized
with xylene and rehydrated in a graded series of ethanol with a
final wash in distilled water. Antigen retrieval involved use of
Target Retrieval Solution (DakoCytomation, Glostrup,
Denmark) in a Decloaking Chamber (Biocare Medical, Walnut
Creek, CA, USA). Sections were stained with F4/80 (pan-
macrophage marker), Ly6G (for neutrophils), STAT3, or CD4
mAb and visualized with use of goat anti-rat Cy3-labeled or
goat anti-rabbit Cy3-labeled secondary antibodies (Jackson
ImmunoResearch). The sections were counterstained with
DAPI (1 µg/mL) and visualized at 400× magnification under a
fluorescent microscope. In situ detection of apoptotic cells
involved terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) according to the manufacturer’s
protocol (Chemicon-Millipore, Billerica, MA, USA). The number
of cells positive for F4/80, Ly6G, STAT3, CD4, and TUNEL
were analyzed by use of AxioVision (Carl Zeiss MicroImaging,
Inc.).
Survival Study
Fulminant hepatitis is associated with a high mortality rate;
therefore, we studied the protective effect of DMY on LPS/D-
GalN−induced mortality in ICR mice. The survival study was
performed using a protocol described previously with
modifications [14]. A total of 40 mice (4 weeks old) were
randomly assigned to four groups (n = 10 per group) for
treatment with: (1) vehicle (0.5% DMSO); (2) LPS/D-GalN; (3)
pretreatment with 1 mg/kg DMY followed by LPS/D-GalN
(DMY1+LPS/D-GalN); and (4) pretreatment with 10 mg/kg
DMY followed by LPS/D-GalN (DMY10+ LPS/D-GalN). Mice
were pretreated i.p. with DMY1 and DMY10 for 3 consecutive
days and 1 h before LPS/D-GalN administration. The mice
were i.p. injected with a combination of LPS (200 µg/kg) and D-
GalN (800 mg/kg) dissolved in PBS. Mortality was monitored
for 48 h after LPS/D-GalN administration.
Primary Metabolome Analysis of Mice Serum by UPLC/
ESI-QTOF MS and Multivariate Analyses
An LC system (ACQUITY UPLC, Waters, Millford, MA, USA)
coupled to a hybrid Q-TOF mass spectrometer was used to
analyze the primary metabolome from serum samples of
treated mice. The works were carried out in the Metabolomics
Core Facility, Academia Sinica, Taiwan. A 10-µL aliquot of sera
was applied to a reverse-phase column (HSS T3 C18, 1.8 µm,
2.1 × 150 mm, Waters, Milford, MA, USA), which was kept in a
column oven at 40 °C. The mobile phase for positive ion mode
consisted of 0.1% formic acid in 2% acetonitrile (buffer A) and
0.1% formic acid in 100% acetonitrile (buffer B). The mobile
phase for the negative ion mode consisted of 2% acetonitrile
(buffer A) and pure 100% acetonitrile (buffer B). The mobile
phase flow rate was 500 µL/min with a 4-min gradient from
0-95% acetonitrile/water. MS involved use of a Waters
Micromass Q-TOF micro Synapt High Definition Mass
Desmethoxyyangonin Prevents Fulminant Hepatitis
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Spectrometer (Synapt HDMS, Waters, Manchester, U.K.)
equipped with electrospray ionization in positive and negative
modes. The optimal conditions for analysis were source
temperature 80 °C, desolvation gas temperature 250 °C, cone
gas flow 50 L/h, desolvation gas flow 800 L/h, capillary voltage
2.2 kV for negative mode and 3.0 for positive mode, sampling
cone voltage 40.0 V, and extraction cone voltage 4.0 V. A lock
mass calibrant of sulfadimethoxine (0.2 µg/mL) in water/
acetonitrile (50:50, v/v) was continuously introduced via the
second ESI probe (Lock-Spray) at a flow rate of 20-40 µL/min,
generating a reference ion for positive ion mode ([M + H]+ =
311.0814 and [M + H]− = 309.0658) to ensure accuracy during
MS. Data were acquired between m/z 50 and 1000 Da with a
0.2-s scan time and a 0.02-s interscan delay and imported to
Markerlynx within Masslynx v4.1 (SCN803, Waters) for peak
detection and alignment. The ion intensities for each peak were
normalized within each sample, and the 3-D data, peak
identifier (RT-m/z pair), sample name, and ion intensity were
introduced to software EZinfo v2.0 for principal component
analysis (PCA), partial least-squares-discriminant analysis
(PLS-DA) and orthogonal projection to latent structures (OPLS)
analysis.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical analyses
were conducted using a SAS program (SAS Institute), and
significance of differences between treatments was determined
by ANOVA. P < 0.05 was considered statistically significant.
Results
DMY Suppresses LPS–induced NO Production and
iNOS Expression in RAW 264.7 Cells
The in vitro LPS−stimulated inflammation in RAW264.7 cell
system was used to evaluate the effect of DMY (Figure 1A) on
NO production. By determination of nitrite level (equivalent to
NO level) in RAW 264.7 culture medium 24 h after LPS
stimulation, DMY dose-dependently inhibited NO production
with IC50 value 70 µM (Figure 1B). The IC50 values for inhibiting
NO production in LPS-induced macrophages for a LPS
antagonist resatorvid and a well-known anti-inflammatory
phytocompound curcumin, used as reference controls in this
study, were of 300 nM and 18 µM, respectively. Moreover,
DMY showed little cytotoxicity to macrophages at a high
concentration, 150~200 µM, because 80% of cells were viable,
as examined by MTT assay (Figure 1B). DMY at the same
concentrations had no cytotoxic effects on murine FL83B
hepatocytes (data not shown).
iNOS catalyzes the oxidative deamination of arginine to
produce NO. We elucidated whether the NO inhibition effect of
DMY was due to its regulation of iNOS gene and protein
expression. The results showed that 62% to 88% of iNOS
mRNA expression was inhibited by 150~200 µM DMY as
compared with LPS alone (Figure 1C), and the iNOS protein
level was more significantly inhibited by DMY in a dose-
dependent manner, with more than 60% of the protein level of
iNOS inhibited at > 75 µM DMY as compared with LPS alone
(Figure 1D). In parallel, we performed an iNOS enzymatic
assay to examine whether the inhibition of NO production by
DMY is also through direct inhibition of iNOS enzyme activity.
Our result showed that the iNOS enzyme activity was not
changed by incubation with 200 µM of DMY as 94.0% and
94.5% of substrate L-[14C] arginine were converted to product
L-[14C] citrulline in the presence or absence of compound DMY,
respectively. Therefore, it was concluded that DMY suppresses
NO production in LPS–stimulated macrophages by down-
regulating iNOS gene and protein expression.
DMY Suppresses LPS–induced Proinflammatory
Mediators in RAW 264.7 Cells
LPS−activated macrophages release proinflammatory
cytokines such as TNF-α and IL-6, which could cause
inflammatory disorders, sepsis or other liver injuries [15]. Thus,
we measured secreted TNF-α and IL-6 in the culture medium
of LPS–stimulated RAW 264.7 cells with or without DMY
treatment. The secretion of TNF-α and IL-6 was decreased with
increasing concentration of DMY. DMY at 50~100 µM could
significantly inhibit the secretion of both TNF-α and IL-6 in
LPS–stimulated macrophages (Figure 1E).
DMY Suppresses Phosphorylated STAT3 Expression
and Attenuates LPS-induced IL-6 Production in
Macrophages
STAT1 and STAT3 are phosphorylated due to activation of
Jak/STAT signaling in LPS−treated macrophages [16]. The
tyrosine phosphorylation of STAT3 promotes the release of
pro-inflammatory cytokines such as IL-6 [6]. We investigated
whether the inhibitory effect of DMY on IL-6 release was
associated with activation of STAT3 and its upstream Jak
kinase in LPS−stimulated RAW 264.7 cells. The level of Jak2
and its phosphorylated form was significantly increased with
LPS stimulation (Figure 2A). Treatment with 50 µM DMY
significantly suppressed phospho-Jak2 but not total Jak2
protein level (Figure 2A). DMY had no effect on the LPS
−induced activation of STAT1 in macrophages, as shown by
the level of phosphorylated STAT1 (pTyr701-STAT1) protein
(Figure 2A). SOCS3 plays a role in negative regulation of IL-6
signaling [14] but was not responsive to DMY treatment (Figure
2B). Because nuclear translocation of STAT3 occurs after Jak2
kinase activation [16], we analyzed nuclear and cytosolic
fractions of pTyr705-STAT3 and STAT3 in addition to their total
protein expression. PARP and α-tubulin were used as internal
and loading controls for nuclear and cytosolic protein fractions,
respectively. DMY significantly suppressed LPS−induced
increasing of STAT3 and phospho-STAT3 levels in the total
proteins and in both nuclear and cytosolic fractions, as
compared with control treatment at 8 h (Figure 2B). These data
suggest that DMY suppression of LPS−induced pro-
inflammatory cytokine production may be mediated in part by
the Jak2/STAT3 signaling pathway.
DMY Inhibits LPS−activated IKK Signaling Pathway in
Macrophages
Because iNOS gene expression can be regulated by the
transcription factor NF-κB, we investigated whether DMY could
affect the activation of IKK and IκBα to regulate nuclear
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Figure 2.  The effect of DMY treatment on Jak/STAT
signaling pathway in LPS−stimulated macrophages.  Cells
were pre-treated with 50 µM DMY for 1 h, then with LPS
treatment for 2, 4, and 8 h. Western blot analysis of (A)
Phospho- and total Jak2 and STAT1 levels, (B) Total STAT3,
phospho-STAT3, and SOCS3 levels and the levels of STAT3
and phospho-STAT3 in nuclear and cytosolic fractions. PARP
and α-tubulin were used as internal control of nuclear and
cytosolic proteins, respectively.
doi: 10.1371/journal.pone.0077626.g002
translocation of NF-κB in macrophages. The level of
phosphorylated forms of IKK and IκBα protein increased with
LPS treatment, which were both suppressed with DMY
pretreatment (Figure 3A). The IKK and IKBα total protein levels
were also lower in DMY–treated cells than cells with LPS
stimulation only. Furthermore, DMY inhibited the LPS−induced
translocation of NF-κB from the cytosol to nucleus in
macrophages (Figure 3B). These data indicate that activation
of IKK with LPS stimulation further activates IκBα for its
ubiquitination and proteasomal degradation to promote NF-κB
nuclear translocation were inhibited by DMY. JNK 1/2 and ERK
1/2, involved in MAPK pathway, have been shown to play a
role in LPS−induced inflammation in macrophages. We found
no difference in protein levels of JNK1/2 and ERK1/2 or their
phosphorylated forms in LPS−stimulated cells with or without
DMY treatment (Figure 3A), so DMY had no effect on the LPS
−activated MAPK pathway in macrophages.
Effect of DMY on LPS/D-GalN−induced Fulminant
Hepatitis in ICR Mice
Because DMY had specific activity in inhibiting LPS−induced
inflammation in macrophages in vitro, we next examined
whether DMY could effectively prevent LPS/D-GalN–induced
fulminant hepatitis in mice. Serum AST and ALT activities have
been used clinically as indicators of hepatic injury [17]. Hence,
we first measured serum AST and ALT levels to evaluate
LPS/D-GalN–induced liver injury in mice. Serum AST and ALT
levels were increased (~2.7-fold) in LPS/D-GalN–challenged
mouse serum as compared with control serum (Figure 4A).
Pretreatment with 1 or 10 mg/kg DMY significantly suppressed
(1.7- to 2.4-fold decrease) LPS/D-GalN–induced increase in
AST and ALT activity in mouse serum (P < 0.05) (Figure 4A).
No statistical difference for the preventive effect of 1 and 10
mg/kg DMY treatments was observed. As compared with
control mouse liver, LPS/D-GalN–challenged liver showed loss
of sinusoidal cells and erythrocyte influx (hemorrhage) as
compared with controls, which was attenuated by pretreatment
with DMY (Figure 4B). Furthermore, DMY significantly
decreased the number of apoptotic cells (TUNEL positive-
stained cells) in the liver tissues of LPS/D-GalN–challenged
mice (Figure 4C). Thus, DMY could effectively protect the
mouse liver against LPS/D-GalN–induced damage.
DMY Pretreatment Prevents LPS/D-GalN–induced
Macrophage and Neutrophil Recruitment and STAT3
Expression in Mouse Liver
Immunohistochemical analysis showed that macrophages
(F4/80-stained cells) and neutrophils (Ly6G-stained cells)
infiltrated into liver tissues with LPS/D-GalN challenge, and
DMY pretreatment could significantly prevent the infiltration
(Figure 5A, B). As well, LPS/D-GalN–increased STAT3 protein
expression was significantly reduced with DMY treatment (P <
0.05) (Figure 5A). Furthermore, on the basis of the
quantification results from the dual staining of F4/80 and
STAT3 (F4/80 & STAT3 positive cells), it is suggested that
most of the STAT3 proteins were originated from the infiltrated
macrophages. These data are in good agreement with the in
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vitro inhibitory effect of DMY on STAT3 protein level in
macrophages with LPS challenge.
Figure 3.  The effect of DMY treatment on NF-κB and MAPK
signaling pathway in LPS−stimulated macrophages.  Cells
were pre-treated with 50 µM DMY for 1 h, then with LPS
treatment for 2, 4, and 8 h. Western blot analysis of (A)
Phospho- and total IKK, IκBα, JNK1/2 and ERK1/2 levels. (B)
Immunofluorescence staining of nuclear translocation of NF-
κB(p65) protein. Cells were stained with DAPI (nuclear marker,
blue) and rabbit anti-p65 antibody (red).
doi: 10.1371/journal.pone.0077626.g003
DMY Inhibits CD4+ Cell Activation and Proliferation, and
Prevents Pathogenic CD4+ Cell Infiltration into Liver
Tissues of Mice Treated with LPS/D-GalN
In LPS/D-GalN−induced fulminant hepatitis, T cells play a
pivotal role in production of various cytokines that lead to liver
injury [18]. We, therefore, investigated whether DMY treatment
can inhibit T cell activation and proliferation, and/or prevent T
cell infiltration into the liver tissue of LPS/D-GalN−treated mice.
Splenic CD4+ cells were purified and activated with anti-CD3
and anti-CD28 mAbs with or without co-incubation with DMY at
25, 50, and 100 µM, respectively. The results of [3H]Thymidine
incorporation and the level of secreted IL-2 in CD4+ cells
indicated that DMY can dose-dependently inhibit CD4+ cell
activation and proliferation (P < 0.05; Figure 6A, B).
Immunohistochemical analysis further showed that the
pathogenic T cells significantly infiltrated into LPS/D-GalN
−treated mouse livers, which were inhibited by DMY treatment
(Figure 6C). These results suggest that the T cell activities
related to the onset of fulminant hepatitis can be modulated by
DMY treatment.
DMY Protects Mice Against LPS/D-GalN−induced
Mortality
Our data have shown that DMY has a hepatoprotective effect
against LPS/D-GalN−induced fulminant hepatitis in mice. We
further examined whether DMY treatment protects against
LPS/D-GalN−induced mortality in mice. The data in Figure 4D
show that only 40% (4/10) of animals survived after 48 h
following LPS/D-GalN insult compared to the vehicle group.
Both pretreatment with DMY1 and DMY10 significantly
improved the survival rate of LPS/D-GalN−treated mice to 90%
(9/10), with P = 0.0257 and P = 0.0217, respectively, compared
to LPS/D-GalN−treated group. This result indicates that DMY
treatment can protect mice from LPS/D-GalN−induced
mortality.
Comparative Metabolomic Analysis of Mouse Serum
We used UPLC/ESI-QTOF MS coupled with multiple pattern
recognition methods such as PCA and PLS-DA to phenotype
the serum metabolome of test mice. Sera from 3 mice from
each treatment group -- vehicle control, LPS/D-GalN challenge,
and pretreatment with both DMY doses before LPS/D-GalN
challenge -- underwent global metabolic profiling in both ESI
positive and negative modes. PCA results can provide an
overview of all observations or samples in a dataset. Each
point in a score plot represents the mass data in an individual
test mouse, and groupings, trends, and outliers can be
observed. The score plots show a similar metabolome when
data points cluster together or closer and when they disperse,
which suggests compositionally different metabolomes. The
score plots from analysis of positive- and negative-mode ions
(Figure 7A, C) showed 2 clusters: LPS/D-GalN–challenged
mice and vehicle and DMY-pretreated mice (except an outlier
of 10 mg/kg DMY treatment in negative ion mode), which
suggests that LPS/D-GalN altered the metabolic fluctuations
that could be prevented by DMY treatment in mice. The
corresponding loading plots for PCA of UPLC/QTOF MS data
present the impact of each metabolite on this PCA clustering
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(Figure 7B, D). The distance of an ion from the origin
represents its contribution to the clustering of different groups
on the PCA.
Metabolite Profiles and Variations in Mouse Serum with
Different Treatments
We identified 29 metabolites from the spectral dataset and
verified them by reference standards (Table 1). From 15 amino
Figure 4.  Protective effects of DMY on LPS/D-GalN−induced acute liver dysfunction in mice.  Mice were pretreated with DMY
(1 and 10 mg/kg) for three consecutive days, then LPS/D-GalN for 8 h. (A) Serum levels of AST and ALT with or without treatment.
Data are mean ± SEM, n = 6. Means without a common letter differ, P < 0.05. (B) Hematoxylin and eosin staining of mouse livers.
(C) TUNEL assay of apoptosis in mouse liver with LPS/D-GalN challenge or DMY treatment. Representative image of each
treatment group is shown. Brownish cells are TUNEL-positive apoptotic cells. (D) Survival rate of LPS/D-GalN-challenged mice with
or without DMY-pretreatment. *,# P < 0.05, significant differences within treatment groups and the LPS/D-GalN group (log rank test).
doi: 10.1371/journal.pone.0077626.g004
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acids identified, the total amino acid concentration was
significantly higher with LPS/D-GalN challenge than the vehicle
control and DMY pretreatment (P < 0.05). Ile/Leu, Phe, and Trp
were significantly increased in level and Pro was decreased in
level in LPS/D-GalN–challenged mouse sera. The 1- and 10-
mg/kg DMY (DMY1 and DMY10) pretreatment could attenuate
the increase in Ile/Leu, Phe, or Trp levels or decrease in Pro
level. As well, the concentrations of gluconeogenic amino
acids, branched-chain amino acids, and aromatic amino acids
were greater with LPS/D-GalN challenge than vehicle
treatment (P < 0.05) and were all lowered by DMY
pretreatment. Furthermore, as compared with vehicle
treatment, LPS/D-GalN challenge decreased the levels of
pyruvate, uric acid, myoinositol, and the reduced form of
glutathione (GSH) in mouse serum. With DMY1 and DMY10
plus LPS/D-GalN, the levels of pyruvate, myoinositol and GSH
were increased (P < 0.05) as compared with LPS/D-GalN
alone, which suggests that DMY can prevent the LPS/D-GalN–
altered metabolism of amino acids and other metabolites
involved in glycolysis in mice. However, DMY could not prevent
the LPS/D-GalN–decreased uric acid level in mouse serum and
could further decrease nicotinamide content, the product of
NAD+ and NADP+, in mice. LPS/D-GalN challenge may cause
some disturbances in fatty acid metabolism, as seen in level of
dodecanoic acid, palmitic acid, and oleic acid, and some
differences in data occurred with DMY treatment, but the
variations were too great to make any suggestions.
Discussion
LPS/D-GalN–induced acute liver injury in mice has been
widely used as an experimental animal model for FHF because
it is similar to the mechanism of FHF observed clinically [19]. In
this model, D-GalN can potentiate the acute toxicity of LPS,
whereby LPS activates macrophages and kupffer cells to
produce TNF-α, then induce hepatocyte apoptosis in the early
stage of LPS/D-GalN–induced hepatitis in mice [20]. Here, we
showed that pretreatment with 1 or 10 mg/kg DMY significantly
suppressed LPS/D-GalN–induced increase in AST and ALT
levels in mouse serum and increased apoptotic cells in mouse
liver. Furthermore, DMY pretreatment prevented the infiltration
of macrophages and neutrophils, inflammatory cell populations,
Figure 5.  Immunohistochemistry of liver tissues from LPS/D-GalN–challenged mice with or without DMY
pretreatment.  Immunofluorescence staining and quantification of DMY inhibiting STAT3 and F4/80 (macrophage) infiltration (A)
and Ly6G (neutrophil) infiltration (B) in LPS/D-GalN−treated mouse liver. Data are mean ± SEM, n = 4. Means without a common
letter differ, P < 0.05.
doi: 10.1371/journal.pone.0077626.g005
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and pathogenic T cells into liver lobules of mice. DMY also
effectively inhibited LPS−stimulated TNF-α secretion in
macrophages and IL-2 secretion in activated primary CD4+ T
cell. We conclude here that DMY protects animals against
fuminant hepatitis induced by LPS/D-GalN at least in part by
attenuating inflammatory cell and CD4+ T cell activities.
Hepatic inflammation is responsible for liver cell damage,
fibrosis and cirrhosis, and LPS plays a critical role in FHF in
humans. In the present report, we used LPS−induced
inflammatory responses and cascades in the macrophage cell
system to elucidate the anti-inflammation and hepatoprotective
activities and the underlying mechanisms of DMY. DMY
suppressed LPS−induced iNOS expression in RAW 264.7
cells, which inhibited NO production in the cells. Moreover,
DMY suppressed LPS−induced TNF-α and IL-6 secretion in
RAW 264.7 cells. Complex intracellular signaling networks,
such as NF-κB and MAPK pathways are involved in regulation
of pro-inflammatory mediator production in response to a broad
range of stimuli, including ischemia/reperfusion, ultraviolet light,
and microbial infection [5]. The translocation of NF-κB to the
Figure 6.  DMY inhibits T cells proliferation ex vivo and T cells infiltration into mouse liver tissues.  (A) Splenic CD4+ T cells
were purified from male ICR mouse and stimulated with vehicle alone or anti-CD3/anti-CD28 mAbs plus 0, 25, 50, or 100 µM of
DMY for 48 h. [3H]Thymidine incorporation in T cells was determined. (B) The concentration of IL-2 in cultural media of T cells was
determined by ELISA. (C) Immunohistochemistry analysis of mouse liver tissues against CD4 mAb. Data are mean ± SEM, n = 3.
Means without a common letter differ, P < 0.05.
doi: 10.1371/journal.pone.0077626.g006
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nucleus depends on the phosphorylation, ubiquitination and
proteolytic degradation of IκB. Nuclear NF-κB can transactivate
several inflammation or immune-related genes such as iNOS,
COX-2, and TNF-α [4]. We found that DMY treatment could
decrease the level of phospho-IKK and phospho-IκBα protein in
LPS−treated cells, as well as prevent nuclear translocation of
NF-κB. These data suggest that DMY inhibition of iNOS
expression at protein and translational levels and NO
production are likely via deregulating an NF-κB-related
signaling pathway. We have observed that DMY treatment did
not alter the expression of COX-2 gene or protein in LPS
−stimulated macrophages (data not shown). Although MAPKs
can transmit environmental stimuli into the nucleus to regulate
the activity of cytokines or other inflammatory mediators such
as TNF-α, IL-6 and NO, in this study, DMY treatment did not
have a discernable effect on LPS−induced activation of JNK
and ERK proteins, as revealed by no changes in levels of
phospho-JNK and phospho-ERK protein in macrophages.
Besides NF-κB and MAPK pathways, STAT signaling has a
role in inflammatory responses. STAT signaling is activated by
upstream JAK kinase via phosphorylation of the tyrosine
residue on STAT1 or STAT3, then dimerization and nuclear
translocation of STAT protein to activate its responsive gene(s)
[16]. Both STAT1 and 3 have an important role in LPS
−stimulated inflammatory responses in macrophages: STAT1
induces iNOS gene expression and promotes NO production
and STAT3 promotes secretion of pro-inflammatory cytokines
such as IL-6 [21,22]. In our study, DMY treatment inhibited the
level of phospho-Jak2 and -STAT3 in LPS−induced
macrophages but did not affect phospho-STAT1 level.
Moreover, DMY−prevented nuclear translocation of STAT3 was
likely via inhibiting STAT3 expression because its protein level
in the cytosolic fraction was decreased with DMY treatment,
which could lead to lower levels of STAT3 and pTyr705-STAT3
detected in nucleus. In addition, DMY effectively reduced
STAT3 protein expression in LPS/D-GalN−treated mouse liver,
so both in vitro and in vivo findings of DMY deregulating STAT3
expression are in good agreement. Nevertheless, the
deregulation of STAT3 protein and its activation by DMY may
lead to inhibiting IL-6 expression. Our results demonstrate that
the anti-inflammatory and hepatoprotective effects of DMY are
by modulating NF-κB and Jak2/STAT3 signaling pathways.
Metabolomics is an emerging technology for analyzing global
or target metabolic profiles to monitor disease development,
Figure 7.  Comparative metabolomic analysis of mouse serum.  Score plots (A, C) and corresponding loading plots (B, D) for
PCA of UPLC/QTOF MS data from mice treated with vehicle control, LPS/D-GalN, and LPS/D-GalN–challenged mice pretreated
with DMY1 and DMY10 (n = 3 in each group). Dashed circles group pairs of samples from LPS/D-GalN–challenged group vs. other
treatment groups. The ions most responsible for the variance of the score plots are indicated by their distance from the origin. The
metabolites are labeled according their retention times in the chromatogram and m/z values.
doi: 10.1371/journal.pone.0077626.g007
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Table 1. Metabolites identified in the serum of mice treated
with vehicle control and LPS/D-GalN, as well as LPS/D-
GalN–challenged mice pretreated with 1 and 10 mg/kg
desmethoxyyangonin (DMY1 and DMY10), respectively.
Metabolites
Vehicle
control
LPS/D-GalN
challenged
DMY1+LPS/D-
GalN
DMY10+LPS/D-
GalN
Alanine
1.06 ±
0.07a
0.86 ± 0.16a 1.01 ± 0.20a 0.96 ± 0.21a
Arginine
1.39 ±
0.09a
1.28 ± 0.36a 1.45 ± 0.37a 1.31 ± 0.24a
Aspartate
0.72 ±
0.09a
0.68 ± 0.31a 0.81 ± 0.31a 0.65 ± 0.26a
Glutamate
3.02 ±
0.65a
2.13 ± 0.79a 2.82 ± 0.51a 2.53 ± 0.42a
Glutamine
3.97 ±
0.18a
4.72 ± 1.16ab 5.74 ± 0.82b 5.51 ± 0.86ab
Glycine
8.87 ±
1.85a
8.21 ± 1.22a 13.62 ± 2.68b 8.64 ± 2.13a
Histidine
2.24 ±
0.60a
3.21 ± 1.33a 2.78 ± 0.28a 2.19 ± 0.40a
Isoleucine/
Leucine
115.02 ±
20.36a
150.73 ±
19.03b.
122.61 ±
17.92ab
127.64 ± 4.68ab
Methionine
12.28 ±
1.81a
11.02 ± 1.86
a 11.58 ± 4.21
a 11.31 ± 1.34a
Phenylalanine
82.76 ±
7.66a
107.85 ±
6.73b
96.97 ± 8.73b 88.45 ± 5.44ab
Proline
1.38 ±
0.04a
1.17 ± 0.14b 1.40 ± 0.06a 1.10 ± 0.08b
Serine
0.58 ±
0.05a
0.51 ± 0.10a 0.66 ± 0.06a 0.59 ± 0.20a
Tryptophan
122.15 ±
7.46a
180.83 ±
36.05b
154.26 ±
12.66ab
162.31 ± 13.19b
Valine
11.07 ±
2.23a
15.03 ± 3.31a 12.35 ± 2.24a 13.03 ± 0.12a
Total amino
acids
366.52 ±
35.22a
488.23 ±
70.22b
428.23 ±
70.22ab
426.22 ± 15.80ab
GAA
225.43 ±
27.26a
289.75 ±
31.05b
255.17 ±
20.68ab
246.57 ± 6.80ab
BCAA
126.09 ±
22.56a
165.76 ±
22.20b
134.95 ±
20.02ab
140.66 ± 4.68ab
AAA
204.90 ±
11.05a
288.68 ±
42.43b
251.23 ±
21.27ab
250.76 ± 15.09ab
Taurine (-)
5.58 ±
1.50a
5.80 ± 2.23a 4.96 ± 1.13a 4.15 ± 0.88a
Glutathione
reduced
0.22 ±
0.06a
0.08 ± 0.02b 0.11 ± 0.06a 0.14 ± 0.03a
Pyruvate
2.29 ±
0.39ab
1.44 ± 0.41b 3.17 ± 1.16a 3.03 ± 0.22a
L-lactate
68.53 ±
20.98a
46.14 ±
11.79a
70.51 ±
22.93a
61.34 ± 6.11a
Myoinositol
30.59 ±
5.14a
21.24 ± 2.80b
23.62 ±
3.23ab
27.15 ± 3.82ab
Nicotinamide
2.15 ±
0.44a
1.88 ± 0.18ab 1.41 ± 0.06c 1.50 ± 0.06bc
Creatine
2.56 ±
0.39a
2.59 ± 0.18a 2.63 ± 0.32a 2.43 ± 0.44a
drug metabolism, and chemical toxicology [23]. It has gained
importance in biotechnology applications such as the diagnosis
and phenotyping of plants, evaluating genetically modified
crops, and analyzing the improvement of compositional quality
of crops [24]. It is also useful in taxonomic classification and
understanding the pharmacological activity of herbal medicines
[25,26]. We used a UPLC/MS platform-based comparative
metabolomics approach to explore the serum metabolic profile
in FHF mice with or without the phytoagent DMY pretreatment.
The metabolic perturbation in multiple pathways with LPS/D-
GalN challenge and DMY treatment are summarized (Figure
8). The total amino acid concentrations of 15 amino acids were
higher in mice with FHF than controls and DMY treated groups,
a similar pattern to the concentrations of gluconeogenic amino
acids (GAA), branched-chain (BCAA) and aromatic amino
acids (AAA). Epidemiological study revealed that patients with
FHF typically show elevated AAA, BCAA and a wide range of
other AAs [27]; in addition, an important clinical parameter in
FHF is decreased BCAA/AAA ratio [28]. We observed these
phenomena in FHF mouse serum, which was also consistently
observed in plasma in mice with fulminant hepatitis as
analyzed by GC/TOF MS [29]. DMY pretreatment could lower
the elevated level of total or different groups of AAs in FHF
mice by mainly decreasing the levels of Ile/Leu, Phe, and Trp.
The level of taurine, a sulfur-containing AA produced by
oxidation of cysteine, was elevated in alcohol-treated 129S
Ppara-null mice with the occurrence of high reactive oxygen
species (ROS) generated [30]. We found no difference in taurin
level in control, DMY-treated, or FHF mice. However, the
antioxidant GSH, a tripeptide formed by amino acids Glu, Cys
Table 1 (continued).
Metabolites
Vehicle
control
LPS/D-GalN
challenged
DMY1+LPS/D-
GalN
DMY10+LPS/D-
GalN
Uric acid
2.39 ±
0.15a
1.81 ± 0.51b 1.36 ± 0.11b 1.57 ± 0.28b
Carnitine
3.21 ±
0.72a
2.35 ± 0.75a 2.71 ± 0.40a 2.44 ± 0.60a
Dodecanoic
acid
343.08 ±
23.71a
646.62 ±
562.93a
418.09 ±
110.56a
684.23 ± 204.50a
Hippuric acid
11.11 ±
3.49a
10.70 ± 5.14a 11.45 ± 3.52a 10.72 ± 6.80a
Palmitic acid
6484.4 ±
737.74a
5396.3 ±
1930.9ab
5835.5 ±
768.71ab
3829.3 ± 994.73b
Stearic acid
1436.0 ±
697.54a
1277.0 ±
200.27a
1571.0 ±
81.51a
828.15 ± 289.16a
Oleic acid
11887.3 ±
1546.5a
8605.8 ±
3955.5a
10393.4 ±
2843.3a
6638.0 ± 2348.5a
Oleamide
1.17 ±
0.30ab
0.96 ± 0.48a 1.35 ± 0.13ab 1.61 ± 0.27b
Note: Data are means ± SEM, n = 5. (P < 0.05, ANOVA). GAA (gluconeogenic
amino acids): aspartate, serine, glycine, glutamine, threonine, alanine, proline,
tyrosine, phenylalanine, valine, leucine, and isoleucine. BCAA (branched chain
amino acids): leucine, isoleucine and valine. AAA (aromatic amino acids):
phenylalanine and tryptophan.
doi: 10.1371/journal.pone.0077626.t001
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and Gly, which can prevent cellular damage caused by ROS,
was significantly decreased in FHF mice as compared with
controls; notably, DMY pretreatment could prevent some
degree of attenuating formation of GSH in FHF mice. These
data suggest an effect of DMY on anti-oxidative stress in
animals.
Normally, blood Ala transports to liver via glucose-alanine
cycle to generate pyruvate, which is a source of carbon atoms
for gluconeogenesis. However, pyruvate can form alanine
through transamination by ALT and is also the substrate for
forming BCAAs (Figure 8). In some cases of severe hepatic
toxicity, such as cirrhosis, BCAAs are used in muscle to create
alanine, which is then shuttled to the liver for facilitating
pyruvate formation. Previously, Ala level was found to be
largely decreased in liver tissue of rats with CCl4-induced acute
hepatic injury [31]. We observed an increase in BCAAs, with no
change in Ala level, a decrease in pyruvate level, and elevated
ALT activity in FHF mouse serum, which suggests that ALT is
involved in affecting the dynamics of BCAA and pyruvate
contents in the mouse. Therefore, LPS/D-GalN−induced
hepatic damage is likely through perturbing amino acid
metabolism, which leads to decreased pyruvate formation via
catalysis of aminotransferases, in turn, attenuating the
glycolysis pathway through the TCA cycle for energy
production in animals with FHF. These alterations in metabolic
network caused by LPS/D-GalN in ICR mouse can be
prevented to a certain degree by DMY treatment.
Previous studies used GC/TOF MS to analyze the changes
in metabolites and metabolic pathways in the plasma of
BALB/c mice with FHF induced by LPS/D-GalN, with plasma
levels of phosphate, glucose, lactate, and β-hydroxybutyrate
suggested to be potential markers of FHF diagnosis and
prognosis [29]. We observed there was no significant change in
the lactate level in both treated and untreated animals, and
myoinositol formed from glucose was found decreased in FHF
mouse serum, but increased in that of mice with DMY
treatment. We did not detect significant levels of metabolites
phosphate, glucose, and β-hydroxybutyrate in our system,
which may be due to different mouse strains (BALB/c vs. ICR
mice) and treatment variables, body fluid tested (plasma vs.
serum), and analytical techniques (GC/MS vs. LC/MS).
We conclude that LPS/D-GalN–induced FHF in animals may
reflect damage in liver function and changes in whole-body
metabolism. Investigation of metabolic changes and metabolic
pathways may provide a rationale for developing nutritional
support or alternative options of therapy for FHF. This study
provides evidence-based health benefits of the active
Figure 8.  Working hypothesis of the metabolic mechanisms of LPS/D-GalN– induced hepatic toxicity and protection by
DMY.  Symbol circle and square represent the relative metabolite changes in the LPS/D-GalN−challenged group and the DMY
treatment group, respectively. The decrease, increase and no difference in levels with statistical significance are presented in green,
red and tan, respectively.
doi: 10.1371/journal.pone.0077626.g008
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compound DMY from rhizome of nutraceutical plant A. pricei
for anti-inflammation and acute hepatitis.
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